Market Place
Sourcing Support
Satsuma & SNBL Receive FDA Acceptance of STS101 NDA for Migraine
26 Nov 2024 //
PR NEWSWIRE
Satsuma Resubmits NDA for STS101 (Migraine Treatment)
30 Oct 2024 //
PR NEWSWIRE
Satsuma And SNBL Announce Publication Of STS101 Study
08 Oct 2024 //
PR NEWSWIRE
Cipla`s Generics Dihydroergotamine Mesylate Receives Approval in US
20 Sep 2024 //
FDA
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100
04 Jan 2023 //
PR NEWSWIRE
Satsuma peels off fresh strip of long-term migraine study data
26 Sep 2022 //
FIERCEPHARMA
Impel Pharma Announces Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Impel NeuroPharma Provides Updates on Trudhesa Launch
18 Jan 2022 //
GLOBENEWSWIRE
Amneal`s Generic Dihydroergotamine Mesylate Receives Approval in the U.S.
04 Jan 2022 //
FDA
Cyrano Appoints John Kollins to its Board of Directors
09 Nov 2021 //
PRNEWSWIRE
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch BOD
12 Oct 2021 //
GLOBENEWSWIRE
Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray
28 Sep 2021 //
GLOBENEWSWIRE
FDA Approvals Roundup: Trudhesa, Brukinsa, Keytruda
08 Sep 2021 //
RAPS
Satsuma Pharmaceuticals to Present at SVB Leerink’s CNS Forum
22 Jun 2021 //
GLOBENEWSWIRE
Amneal Announces DHE Autoinjector NDA for Migraines and Cluster Headaches
07 Jun 2021 //
BUSINESSWIRE
Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™
06 Aug 2020 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1
28 Jan 2020 //
GLOBENEWSWIRE
Hikma Pharm’s Generic Dihydroergotamine Mesylate Receives Approval In US
21 Sep 2017 //
FDA
Firms Team Up To Sustain Natural Pilocarpine
17 Mar 2015 //
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.